Royalty Pharma Analyst Price Targets - Benzinga

SPY757.12+0.19%QQQ692.74+0.33%BTC/USD78,448.23+0.29%DIA517.65+0.10%GLD356.15+0.10%TLT81.65−0.23%

Premium Services

Royalty Pharma PLC

RPRXNASDAQ

Trade with Public

Trade with Public

$67.18

1.251.9%

Last update: Oct 30, 5:27 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Royalty Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Royalty Pharma (RPRX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$56Upside to Avg. PT-17.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$65→$67
Sep 8, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$65→$68
Aug 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$58→$62
Jul 13, 2026	TD Cowen	Steve Scala	PT Raise	Buy	$50→$65
May 7, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$66
May 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$50→$58
Apr 21, 2026	UBS	Ashwani Verma	PT Raise	Buy	$51→$57
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$61→$63
Jan 30, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$38→$49
Jan 27, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$48→$50
Dec 11, 2025	TD Cowen	Steve Scala	PT Raise	Buy	$42→$45
Oct 10, 2025	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$55→$54
Sep 30, 2025	Goldman Sachs	Asad Haider	Initiate	Buy	$42
Jul 22, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$40→$42
Jul 10, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$51→$54
Oct 25, 2024	Citigroup	Andrew Baum	PT Cut	Buy	$60→$40
Aug 14, 2024	Goldman Sachs	Chris Shibutani	PT Raise	Buy	$50→$51
Jul 11, 2024	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$48→$51
Jun 3, 2024	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$28
Apr 12, 2024	B of A Securities	Geoff Meacham	PT Cut	Buy	$40→$38

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $66.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.

Benzinga Newsdesk